provided support in the form of research funding for this study to JRS, BAC and ASW. The

- 21 KJA, PMcC and GRK.
- 22 **Clinical Trial Registration:** Date of Registration: September 12, 2014; First Patient Enrolled:
- October 13, 2014; Identification No.: NCT02237950; clinicaltrials.gov
- 24 **Paper Presentation:** The 46<sup>th</sup> Annual Meeting of The Infectious Diseases Society for Obstetrics
- and Gynecology (IDSOG), Big Sky, Montana, USA, August 8-10, 2019
- **26 Author for Correspondence:**
- 27 Jeremy R.A. Paull, PhD

- 28 4-6 Southampton Crescent, Abbotsford, Victoria 3067, Australia
- 29 Telephone (Work): +61 3 8532 2736
- 30 Email: jeremy.paull@starpharma.com
- Word Count: Abstract=496; Main text=2993

Condensation 33 34 This Phase 3 randomized controlled trial demonstrated efficacy and safety of Astodrimer 1% Gel 35 for the prevention of recurrent bacterial vaginosis. **Short Title** 36 37 Astodrimer Gel for prevention of bacterial vaginosis. 38 AJOG at a Glance 39 A. Why was the study conducted? 40 The study was conducted to confirm the efficacy and safety of Astodrimer 1% Gel, which has a 41 novel, non-antibiotic mechanism of action related to disruption of biofilms, for the prevention of 42 recurrent bacterial vaginosis. B. What are the key findings? 43 44 Astodrimer 1% Gel administered every second day for 16 weeks, was effective and superior to 45 placebo for the prevention of recurrent bacterial vaginosis in women with a history of recurrent 46 BV, and was well-tolerated. 47 C. What does this study add to what is already known? 48 These results support the use of Astodrimer 1% Gel, which was previously shown to be effective 49 for the treatment of women with bacterial vaginosis, as a safe and effective product for the 50 prevention of recurrent bacterial vaginosis.

53

54

55

56

57

58

59

60

61

62

63

64

65

66

67

68

69

70

71

72

73

4

placebo (Kaplan-Meier survival curves, P = .007). Recurrence of subject-reported symptoms at

or by Week 16 was also significantly lower in the astodrimer arm compared with placebo

74

75

76

77

78

79

80

81

82

83

84

85

86

87

88

89

90

91

92

93

94

VivaGel

### Introduction

96

97

98

99

100

101

102

103

104

105

106

107

108

109

110

111

112

113

114

115

116

Bacterial vaginosis (BV) is the most common vaginal infection and approximately twice as common as vulvovaginal candidiasis. BV recurrence rates are high at 43% to 52% within 3 to 6 months of treatment.<sup>2</sup> BV is a risk factor for serious medical sequelae, including pre-term birth. and acquisition and transmission of human immunodeficiency virus (HIV) and other sexually transmitted infections.<sup>3,4</sup> Recurrent BV has particularly significant psychosocial impacts on women, including severely affecting self-esteem and sex life, and carries a high economic burden.<sup>5,6</sup> In the US, there are no approved therapies and there have been no other large, adequately powered, well-controlled studies of interventions for prevention of recurrent BV. Antibiotic therapies are used prophylactically off-label over extended periods for reducing recurrence of BV, but are associated with increased risk of side effects<sup>7</sup> and potential for antibiotic resistance development. It is not realistic to expect a one-time therapy to provide long-term cure of BV, given the lifestyle factors associated with recurrence. Therefore, therapies for preventing BV recurrence that are suitable for longer-term use are urgently required. 10,11 Astodrimer sodium (VivaGel, Starpharma Pty Ltd, Melbourne, Victoria, Australia) is a highly branched, polyanionic dendrimer that blocks attachment of bacteria to cells, preventing formation of bacterial biofilms, which are central to the pathogenesis of BV and not targeted by existing therapies. 12,13,14,15,16 Astodrimer Gel was effective for treatment of women with BV, achieving clinical cure at the end of a 7-day treatment course, and was well-tolerated and not systemically absorbed. 17,18

118

119

120

121

122

123

124

125

126

127

128

129

130

131

132

133

134

135

136

137

7

applicators. Each applicator contained a single dose (5 g) and was individually overwrapped in a

139

140

141

142

143

144

145

146

147

148

149

150

151

152

153

154

155

156

157

158

159

sealed pouch. Seventeen overwrapped applicators (14 doses and 3 spare) were packed in a tamper-evident carton labelled with a unique study medication number, which was allocated along with a unique patient identification number using an interactive randomization system. One carton, sufficient for 4 weeks' dosing, was dispensed to each woman at Baseline, and at Week 4, 8 and 12 study visits. Women self-administered a dose vaginally, every second day for 16 consecutive weeks (56 doses total) and attended visits for assessment of BV and adverse events (AEs) every 4 weeks during, and for 12 weeks after end of, treatment. Both care providers and patients were unaware of treatment allocations. Women could withdraw from the study at any time. Women who had a recurrence of BV prior to Week 16 stopped treatment, ended the study and were offered BV therapy in line with local practice. A woman was considered to have completed the study if she reached the final follow-up visit (Week 28) recurrence free or had confirmed BV recurrence at any time. **Study Population** Women aged 18-45 years with a current diagnosis of BV, defined as presence of  $\geq 3$  Amsel criteria (discharge; vaginal fluid pH >4.5; >20% clue cells; and/or positive 10% potassium hydroxide whiff test), <sup>19</sup> Nugent score (NS) of 4-10<sup>20</sup> and self-report of characteristic BV symptoms (abnormal vaginal odor and/or discharge), and a history of recurrent BV defined as at least 2 documented episodes of BV in the past year, were enrolled in the open-label phase. Women who were pregnant, planning to become pregnant, lactating, or within 3 months of last pregnancy outcome at enrollment, women testing positive for urinary tract infection (UTI),

Chlamydia trachomatis, Neisseria gonorrhea or Trichomoniasis vaginalis infections, or positive

161

162

163

164

165

166

167

168

169

170

171

172

173

174

175

176

177

178

179

180

AEs were monitored throughout the study.

**Statistical Analyses** 

181

182

183

184

185

186

187

188

189

190

191

192

193

194

195

196

197

198

199

200

Primary and secondary efficacy analyses using logistic regression, with missing BV recurrence data at Week 16 imputed as recurrence and treatment as the only factor in the model, were performed on the modified intent-to-treat (mITT) population, which comprised all women randomized who administered  $\geq 1$  dose of study product. This population was also used to determine safety endpoints. The primary efficacy endpoint was also analyzed for population subgroups based on Nugent category at screening and baseline, method of contraception, race, sexual activity during the study, change in sexual partner, use of a vaginal product, number of previous BV episodes, body mass index (BMI) and socio-economic status. Categorical variables were summarized using frequency counts and percentages of patients in each category. Descriptive statistics were calculated for each continuous variable. Survival curves for time to recurrence were estimated using Kaplan-Meier methodology. A logrank test was used to test the difference between survival curves of the treatment arms. Hazard of BV recurrence was analyzed within the framework of the Kaplan-Meier survival analysis. Statistical analyses were performed using SAS (Version 9.2; SAS Institute, Cary, NC). **Sample Size Calculation** Assuming BV recurrence rates of 32% and 45% for Astodrimer Gel and placebo, respectively, a sample size of 308 evaluable participants per treatment arm provided 90% power with a 2-sided test to detect a treatment difference with alpha significance level of 0.05. Therefore, 310 per

202

203

204

205

206

207

208

209

210

211

212

213

214

215

216

217

218

219

220

11

in the placebo group, with exception of vaginal fluid pH (Table 2). In addition, a lower

222

223

224

225

226

227

228

229

230

231

232

233

234

235

236

237

238

239

240

241

242

proportion of patients receiving astodrimer compared with placebo had BV recurrence at or by Week 16 based on NS 7-10, and the composite of  $\geq 3$  Amsel criteria and NS  $\geq 4$  (Table 2). During the 12-week follow-up phase, recurrence of BV (≥3 Amsel criteria) in women given astodrimer was lower than in those given placebo but the differences were not statistically significant (Table 3). Recurrence of patient-reported BV symptoms of vaginal odor and/or discharge was statistically significantly lower in the astodrimer arm compared with placebo up to 8 weeks after cessation of therapy (Table 3). QoL scores were similar between treatment groups at screening and baseline. Total CSFQ-F scores at or by Week 16 increased slightly in the astodrimer group and were slightly decreased in the placebo group, with a mean change from baseline of +1.0 (95% CI: -0.4, 2.3) and -0.8 (95% CI: -3.0, 1.3), respectively, suggesting a slightly improved sexual function in the astodrimer group. The change in BISF-W composite score was in line with the CSFQ-F findings and changed by +1.6 (95% CI: -0.5, 3.7) in the astodrimer group but only by +0.1 (95% CI: -2.0, 2.1) in the placebo group. There were no remarkable differences between groups in terms of mean score change for the SF-36v2 and Global Health Outcome questionnaires. Subgroup recurrence rates were in line with those for the mITT analyses. The Breslow-Day test for homogeneity of odds ratios of astodrimer versus placebo was non-significant for each subgroup factor (P > .150, except Age, P = .098); data not shown. Lower recurrence rates at or by Week 16 for women randomized to astodrimer compared to placebo were statistically significant for several subgroup categories, including women with screening NS of 7-10 (46.2% [108/234] vs 57.7% [128/222], P = .014), black women (53.7% [79/147] vs 68.1% [96/141],

244

245

246

247

248

249

250

251

252

253

254

255

256

257

258

259

260

261

262

263

264

P = .013), women who had penile-vaginal sexual acts during the treatment period (38.9%) [96/247] vs 50.6% [121/239], P = .009), and women who used condoms during treatment period (33.0% [29/88] vs 49.4% [44/89], P = .027).Safety/tolerability The overall incidence of AEs was 54.1% (159/294) for Astodrimer Gel and 47.4% (138/291) for placebo (Table 4). AEs potentially treatment-related occurred in 12.6% (37/294) of astodrimer patients and 11.3% (33/291) for placebo. Most AEs were mild or moderate in intensity, and self-limiting. During treatment, 1.7% (5) women in each group reported severe AEs, but none were considered treatment related. In the astodrimer group, 1 participant discontinued treatment due to menorrhagia and 1 participant due to vulvoyaginal candidiasis, which was considered to be possibly related to treatment. In the placebo group, 1 participant discontinued due to each of vulvoyaginal candidiasis, type 2 diabetes mellitus, headache and abdominal pain, and 1 participant discontinued after experiencing vaginal inflammation, vulvovaginal burning sensation, vulvovaginal pruritus and BV considered possibly treatment related. Serious AEs (other than pregnancy) were reported for 3/294 (1.0%) women in the astodrimer group and 3/291 (1.0%) in placebo, and none was considered to be potentially treatment related. Vulvovaginal candidiasis was reported in 18.0% (53/294) and 13.7% (40/291) women in the astodrimer and placebo groups, respectively, during treatment and 20.1% [59/294] vs 17.2% [50/291] for the overall study period. Vulvovaginal candidiasis considered potentially treatmentrelated was reported in 6.8% (20/294) and 4.8% (14/291) of women using astodrimer or placebo, respectively, during treatment. During follow-up, vulvovaginal candidiasis rates were 4.1%

266

267

268

269

270

271

272

273

274

275

276

277

278

279

280

281

282

283

284

285

14

long-term maintenance therapy for reducing recurrent BV,<sup>24</sup> even without confirmatory evidence.

287

288

289

290

291

292

293

294

295

296

297

298

299

300

301

302

303

304

305

306

The proportion of women with known BV recurrence (i.e., missing data not imputed) for Astodrimer 1% Gel (34.9% [88/252] vs 46.6% [116/249] for placebo) was comparable with that seen in a similarly designed, but substantially smaller study of topically applied metronidazole gel given for 16 weeks (25.5%). The difference in recurrence rates between astodrimer and placebo narrowed progressively after end of treatment, but women in the astodrimer group recurred later than placebo, and therefore had more recurrence free days. In addition, recurrence of symptoms of BV was statistically significantly lower for astodrimer compared with placebo up to Week 24, 8 weeks after end of therapy, indicating a clinically meaningful residual benefit. Treatment with astodrimer helped maintain normal vaginal flora, with lower BV recurrence rates as determined by Nugent score and the combination of Amsel criteria and Nugent score. Overall, treatment with Astodrimer 1% Gel for the prevention of BV recurrence was superior to placebo across all efficacy endpoints: clinical (Amsel criteria), patient reported (symptoms) and microbiological (Nugent score). Results – safety profile The proportion of women with vulvovaginal candidiasis receiving astodrimer (18% during treatment, 20.1% overall) was similar to placebo and less than half that reported during a study of 16 weeks' treatment with topical metronidazole 0.75% gel (43.1% vs 20.5% in placebo). The slightly higher proportion of women with UTI for astodrimer compared with placebo could be potentially explained by the longer symptom-free period associated with use of astodrimer allowing a resumption of a more normal frequency of intercourse, consistent with slightly higher

308

309

310

311

312

313

314

315

316

317

318

319

320

321

322

323

324

325

326

327

sexual functioning scores observed in this study. In any case, the incidence of uncomplicated UTI in young, sexually active women in the US is reported to be approximately 0.5 episodes per person per year. 25 The incidence in women using astodrimer in this study was 0.37 episodes per person per year. There were no other notable differences in AEs reported for astodrimer and placebo. **Clinical implications** Astodrimer is a novel dendrimer administered vaginally and is not systemically absorbed. Data show that it inhibits formation of and disrupts biofilms due to its ability to block bacterial adhesion. Given this profile, astodrimer avoids issues typically associated with conventional antibiotics, such as systemic side effects and antibiotic resistance, and is suitable as an effective and safe alternative for the long-term management of recurrent BV, addressing an unmet medical need. Subgroup analyses showed statistically significant differences in clinical response between astodrimer and placebo in population groups with recognized risk factors for BV, such as black women, those engaging in penile-vaginal sexual acts during the treatment period, and a high screening NS of 7-10, suggesting clear benefit of the preventive treatment with astodrimer in these high-risk groups. **Research implications** 

The findings of this Phase 3 study support the clinical utility of Astodrimer 1% Gel as a novel treatment for prevention of BV recurrence in women suffering from recurrent BV. The product has regulatory approval in Europe, Australia and a number of countries in Asia, and additional

329

330

331

332

333

334

335

336

337

338

339

340

341

342

343

344

345

346

347

348

17

non-antibiotic mechanism of action related to blocking of biofilms. The product acts locally and

- is not systemically absorbed, and offers patients and clinicians a unique treatment option that
- avoids potential issues associated with existing conventional antibiotics.

# Acknowledgments

The authors would like to thank all the patients who were involved in the study and the Principal Investigators for involvement with the clinical trial. Editorial and medical writing assistance was provided by Angela Hart, MSc, of Quanticate UK Ltd, supported by Starpharma Pty Ltd, the manufacturer of Astodrimer Gel. The authors were fully responsible for the content, editorial decisions, and opinions expressed in the current article. The authors did not receive an honorarium related to the development of this manuscript.

#### References

359

<sup>&</sup>lt;sup>1</sup> Barbone F, Austin H, Louv WC, Alexander WJ. A follow-up study of methods of contraception, sexual activity, and rates of trichomoniasis, candidiasis, and bacterial vaginosis. Am J Obstet Gynecol 1990;163(2):510-4.

<sup>&</sup>lt;sup>2</sup> Bradshaw CS, Morton AN, Hocking J, et al. High recurrence rates of bacterial vaginosis over the course of 12 months after oral metronidazole therapy and factors associated with recurrence. J Infect Dis 2006;193:1478-86.

<sup>&</sup>lt;sup>3</sup> Hillier SL, Nugent RP, Eschenbach DA, et al. Association between bacterial vaginosis and preterm delivery of a low-birth-weight infant. The Vaginal Infections and Prematurity Study Group. N Engl J Med 1995;333:1737-42.

<sup>&</sup>lt;sup>4</sup> Schwebke JR. New concepts in the etiology of bacterial vaginosis. Current Infectious Disease Reports 2009;11(2):143-7.

<sup>&</sup>lt;sup>5</sup> Bilardi JE, Walker S, Temple-Smith M, et al. The burden of bacterial vaginosis: Women's experience of the physical, emotional, sexual and social impact of living with recurrent bacterial vaginosis. PLoS ONE 2013;8(9):e74378.

<sup>&</sup>lt;sup>6</sup> Peebles K, Velloza J, Balkus JE, McClelland RS, Barnabas RV. High global burden and costs of bacterial vaginosis: A systematic review and meta-analysis. Sex Transm Dis 2019;46(5):304-11.

<sup>&</sup>lt;sup>7</sup> Sobel JD, Ferris D, Schwebke J, et al. Suppressive antibacterial therapy with 0.75% metronidazole vaginal gel to prevent recurrent bacterial vaginosis. Am J Obstet Gynecol 2006. 194:1283-9.

<sup>&</sup>lt;sup>8</sup> Beigi RH, Austin MN, Meyn LA, Krohn MA, Hillier SL. Antimicrobial resistance associated with the treatment of bacterial vaginosis. Am J Obstet Gynecol 2004;191:1124-9.

<sup>&</sup>lt;sup>9</sup> Bradshaw CS, Vodstrcil LA, Hocking JS, et al. Recurrence of bacterial vaginosis is significantly associated with posttreatment sexual activities and hormonal contraceptive use. Clin Infect Dis 2013;56(6):777-86.

- <sup>10</sup> Bradshaw CS, Brotman RM. Making inroads into improving treatment of bacterial vaginosis striving for long-term cure. BMC Infect Dis 2015;15:292-303.
- <sup>11</sup> Bradshaw CS, Sobel JD. Current treatment of bacterial vaginosis Limitations and need for innovation. J Infect Dis 2016;214(Suppl 1):S14-20.
- <sup>12</sup> Swidsinski A, Mendling W, Loening-Baucke V, et al. Adherent biofilms in bacterial vaginosis. Obstet Gynecol 2005;106(5 Pt 1):1013-23.
- <sup>13</sup> Muzny CA, Schwebke JR. Biofilms: An underappreciated mechanism of treatment failure and recurrence in vaginal infections. Clin Infect Dis 2015;61(4):601-6.
- <sup>14</sup> Machado D, Castro J, Palmeira-de-Oliveira A, Martinez-de-Oliveira J, Cerca N. Bacterial vaginosis biofilms: Challenges to current therapies and emerging solutions. Front Microbiol 2016;6:1528.
- <sup>15</sup> McGowan I, Gomez K, Bruder K, et al. Phase 1 randomized trial of the vaginal safety and acceptability of SPL7013 Gel (VivaGel) in sexually active young women (MTN-004). AIDS 2011;25(8):1057-64.
- <sup>16</sup> O'Loughlin J, Millwood IY, McDonald HM, Price CF, Kaldor JM, Paull JRA. Safety, tolerability, and pharmacokinetics of SPL7013 Gel (VivaGel): A dose-ranging, phase I study. Sex Transm Dis 2010;37(2):100-4.
- <sup>17</sup> Waldbaum AS, Schwebke JR, Paull JRA, et al. A phase 2, double-blind, multicenter, randomized, placebo-controlled, dose-ranging study of the efficacy and safety of Astodrimer Gel for the treatment of bacterial vaginosis. PLoS ONE 2020;15(5):e0232394.
- <sup>18</sup> Chavoustie SE, Carter BA, Waldbaum AS, et al. Two phase 3, double-blind, placebo-controlled studies of the efficacy and safety of Astodrimer 1% Gel for the treatment of bacterial vaginosis. Eur J Obstet Gynecol Reprod Biol 2020;245:13-8.
- <sup>19</sup> Amsel R, Totten PA, Spiegel CA, Chen KCS, Eschenbach D, Holmes KK. Nonspecific vaginitis; Diagnostic criteria and microbial and epidemiologic associations. Am J Med 1983;74:14-22.
- <sup>20</sup> Nugent RP, Krohn MA, Hillier SL. Reliability of diagnosing bacterial vaginosis is improved by a standardized method of gram stain interpretation. J Clin Microbiol 1991;29:297-301.

- <sup>21</sup> Reichman O, Akins R, Sobel JD. Boric acid addition to suppressive antimicrobial therapy for recurrent bacterial vaginosis. Sex Transm Dis 2009;36(11):732-4.
- <sup>22</sup> McClelland RS, Balkus JE, Lee J, et al. Randomized trial of periodic presumptive treatment with high-dose intravaginal metronidazole and miconazole to prevent vaginal infections in HIV-negative women. J Infect Dis 2015;211(12):1875-82.
- <sup>23</sup> Cohen CR, Wierzbicki MR, French AL, et al. Randomized trial of lactin-V to prevent recurrence of bacterial vaginosis. N Engl J Med 2020;382:1906-15.
- <sup>24</sup> Workowski KA, Bolan GA. Centers for Disease Control and Prevention (CDC). Sexually transmitted diseases treatment guidelines. MMWR-Morbid Mortal W 2015;64(RR-03):1-137.
- <sup>25</sup> Medina M, Castillo-Pino E. An introduction to the epidemiology and burden of urinary tract infections. Ther Adv Urol 2019;11:3-7.

## **Tables**

Table 1: Screening Characteristics (mITT population), by Treatment Group

	Astodrimer Gel	Placebo	
	(N=294)	(N=291)	
Age (yr)			
Mean [SD]	31.6 [7.23]	31.6 [6.99]	
Range	18 to 45	18 to 45	
Race, n (%)			
Black	147 (50.0)	141 (48.5)	
White	115 (39.1)	113 (38.8)	
All Others <sup>a</sup>	32 (10.9)	37 (12.7)	
Ethnicity, n (%)			
Not Hispanic or Latino	209 (71.1)	206 (70.8)	
Hispanic or Latino	85 (28.9)	85 (29.2)	
Screening Nugent score, n (%)			
0 to 3	3 (1.0)	1 (0.3)	
4 to 6	57 (19.4)	67 (23.0)	
7 to 10	234 (79.6)	222 (76.3)	
Missing	0	1 (0.3)	
Number of BV episodes in 12 months			
prior to enrolment <sup>b</sup>			
1	2 (0.7)	0	
2	187 (63.6)	198 (68.0)	
3 to 4	94 (32.0)	82 (28.2)	
≥5	11 (3.7)	11 (3.8)	

BV=bacterial vaginosis; SD=standard deviation

<sup>&</sup>lt;sup>a</sup> All Others = American Indian or Alaskan Native, Asian, Native Hawaiian or Other Pacific Islander, Other

<sup>&</sup>lt;sup>b</sup> Not including a current episode

Table 2: Efficacy Outcomes at or by Week 16 (mITT population), by Treatment Group

	Astodrimer	Placebo				
<b>BV</b> Recurrence Endpoint	n/N (%) [95% CI <sup>a</sup> ]	n/N (%) [95% CI <sup>a</sup> ]	RR (95% CI <sup>b</sup> )	P value <sup>b</sup>		
Primary Endpoint						
≥3 Amsel criteria	130/294 (44.2) [38.5, 50.1]	158/291 (54.3) [48.4, 60.1]	0.81 (0.69, 0.96)	0.015		
Subject-reported BV Symptoms						
Vaginal Discharge	56/275 (20.4) [15.8, 25.6]	79/276 (28.6) [23.4, 34.3]	0.71 (0.53, 0.96)	0.025		
Vaginal Odor	57/275 (20.7) [16.1, 26.0]	87/276 (31.5) [26.1, 37.4]	0.66 (0.49, 0.88)	0.004		
Vaginal Discharge and/or Odor	75/269 (27.9) [22.6, 33.6]	108/266 (40.6) [34.6, 46.8]	0.69 (0.54, 0.87)	0.002		
Individual Amsel Criteria	'	,		1		
Vaginal Discharge	97/276 (35.1) [29.5, 41.1]	125/276 (45.3) [39.3, 51.4]	0.78 (0.63, 0.95)	0.015		
Positive Whiff Test	99/276 (35.9) [30.2, 41.8]	119/276 (43.1) [37.2, 49.2]	0.83 (0.68, 1.02)	0.082		
Clue Cells ≥20%	104/274 (38.0) [32.2, 44.0]	132/273 (48.4) [42.3, 54.5]	0.79 (0.65, 0.95)	0.014		
pH >4.5	175/276 (63.4) [57.4, 69.1]	175/276 (63.4) [57.4, 69.1]	1.00 (0.88, 1.14)	1.000		
<b>Composite Definition</b>	81/276 (29.3) [24.0, 35.1]	111/276 (40.2) [34.4, 46.3]	0.73 (0.58, 0.92)	0.008		
Nugent Score 7-10	95/240 (38.5) [32.4, 44.8]	135/273 (49.5) [43.4, 55.5]	0.78 (0.64, 0.95)	0.012		

BV=bacterial vaginosis; CI=confidence interval; RR=relative risk 
<sup>a</sup> Clopper Pearson CI 
<sup>b</sup> Wald CI and *P* value

Table 3: Efficacy Outcomes During Follow-up (mITT population), by Treatment Group

	Astodrimer	Placebo					
Endpoint	n/N (%) [95% CI <sup>a</sup> ]	n/N (%) [95% CI <sup>a</sup> ]	RR (95% CI <sup>b</sup> )	P value <sup>b</sup>			
BV Recurrence (≥3 Amsel criteria)							
Week 20	191/294 (65.0) [59.2, 70.4]	203/291 (69.8) [64.1, 75.0]	0.93 (0.83, 1.04)	0.217			
Week 24	194/294 (66.0) [60.3, 71.4]	213/291 (73.2) [67.7, 78.2]	0.90 (0.81, 1.00)	0.059			
Week 28	197/294 (67.0) [61.3, 72.4]	206/291 (70.8) [65.2, 76.0]	0.95 (0.85, 1.06)	0.323			
Subject-reported BV Symptoms – Vaginal Discharge and/or Odor							
Week 20	87/269 (32.3) [26.8, 38.3]	110/266 (41.4) [35.4, 47.5]	0.78 (0.62, 0.98)	0.031			
Week 24	97/269 (36.1) [30.3, 42.1]	121/266 (45.5) [39.4, 51.7]	0.79 (0.64, 0.97)	0.027			
Week 28	107/269 (39.8) [33.9, 45.9]	124/266 (46.6) [40.5, 52.8]	0.85 (0.70, 1.04)	0.111			

BV=bacterial vaginosis; CI=confidence interval; RR=relative risk 
<sup>a</sup> Clopper Pearson CI 
<sup>b</sup> Wald CI and *P* value

Parameter	Astodrimer N=294 n (%)	Placebo N=291 n (%)
Patients with ≥1 AE	159 (54.1)	138 (47.4)
Patients with ≥1 AE considered by investigator to be potentially related to study treatment	37 (12.6)	33 (11.3)
Patients with ≥1 severe AE during treatment	5 (1.7)	5 (1.7)
Patients with ≥1 serious AE (other than pregnancy)	3 (1.0)	3 (1.0)
Patients who discontinued treatment due to AE (other than pregnancy)	2 (0.7)	5 (1.7)
Most frequent AEs during treatment (incidence ≥2% for astodrimer)		
Vulvovaginal candidiasis	53 (18.0)	40 (13.7)
Urinary tract infection	23 (7.8)	7 (2.4)
Headache	15 (5.1)	18 (6.2)
Abdominal pain (upper, lower, not specified)	11 (3.7)	8 (2.7)
Vaginal discharge	9 (3.1)	4 (1.4)
Nasopharyngitis	8 (2.7)	13 (4.5)
Upper respiratory tract infection	8 (2.7)	6 (2.1)
Vulvovaginal pruritus	7 (2.4)	10 (3.4)

AE=adverse event

## **Figure Legends**

Figure 1. CONSORT diagram

**Figure 2.** Kaplan-Meier survival curves for time to recurrence of bacterial vaginosis at or by Week 16 (modified intent-to-treat population)

<sup>&</sup>lt;sup>a</sup> Log-rank test for the difference between the survival curves of the two treatment groups



